Ethyl 4,5-Bis(2-Methoxyethoxy)-2-Nitrobenzoate Bulk Price 2026
- Market Outlook: 2026 pricing forecasts indicate stability for high-purity kinase inhibitor intermediates despite raw material fluctuations.
- Technical Specs: CAS 179688-26-7 requires strict control of nitro-reduction impurities and ether side-chain consistency.
- Procurement: Bulk contracts offer significant cost reductions compared to gram-scale research quantities for commercial synthesis.
The pharmaceutical landscape for kinase inhibitors continues to expand, driving sustained demand for specialized aromatic building blocks. Among these, Ethyl 4,5-Bis(2-Methoxyethoxy)-2-Nitrobenzoate (CAS: 179688-26-7) serves as a critical precursor in the production of targeted therapies. As we approach 2026, procurement managers and process chemists must evaluate not only the bulk price but also the technical capability of suppliers to maintain industrial purity standards. This compound, often categorized as a key Erlotinib intermediate, requires meticulous synthesis to ensure downstream reaction efficiency.
For large-scale manufacturing, the consistency of the ether side chains and the integrity of the nitro group are paramount. Variations in purity can significantly impact the yield of subsequent reduction and coupling steps. NINGBO INNO PHARMCHEM CO.,LTD. has established itself as a premier global manufacturer capable of delivering this complex Nitrobenzoate derivative with the rigorous quality assurance required for commercial drug substance production.
Technical Specifications and Quality Standards
When sourcing this chemical building block, technical buyers must verify molecular consistency against established pharmacopeial standards. The molecular formula C15H21NO8 and molecular weight of 343.33 g/mol dictate specific handling and storage protocols. Below is a detailed technical specification table relevant for quality control departments.
| Parameter | Specification |
|---|---|
| CAS Number | 179688-26-7 |
| Molecular Formula | C15H21NO8 |
| Molecular Weight | 343.33 g/mol |
| Appearance | Off-white to Light Yellow Solid |
| Purity (HPLC) | >98.5% (Pharmaceutical Grade) |
| Storage Conditions | 2-8°C, Protected from Light and Moisture |
| Documentation | COA, MSDS, Method of Analysis Provided |
Achieving pharmaceutical grade status requires more than simple recrystallization. The synthesis route typically involves the nucleophilic substitution of a dihydroxy nitrobenzoate precursor with 2-methoxyethanol derivatives under basic conditions. Controlling the reaction temperature and stoichiometry is essential to prevent mono-substitution impurities or over-alkylation. Advanced manufacturers utilize preparative HPLC and rigorous solvent stripping to ensure the final product meets the stringent requirements for oncology drug synthesis.
Volume-Based Pricing Tiers for Bulk Orders
Pricing for specialized intermediates fluctuates based on order volume, purity requirements, and lead times. In the B2B chemical market, unit costs decrease significantly as quantities transition from laboratory scale to industrial metric tons. For 2026, buyers should anticipate tiered pricing structures that reward long-term supply agreements.
Small-scale purchases (grams to low kilograms) often incur premium pricing due to the overhead of quality control testing and packaging. Conversely, bulk procurement allows manufacturers to optimize batch sizes, reducing solvent waste and energy consumption per unit. When evaluating suppliers for Ethyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate, it is crucial to request a detailed cost breakdown that includes packaging, freight, and customs clearance for international shipments.
Typical volume tiers for this intermediate include:
- Research Scale (10g - 100g): Highest cost per gram, intended for route scouting and initial assay development.
- Pilot Scale (1kg - 10kg): Moderate pricing, suitable for process validation and small clinical batch production.
- Commercial Scale (100kg+): Lowest cost per kilogram, optimized for full-scale GMP manufacturing of the final API.
Comparing Gram Scale vs Industrial Kilogram Costs
The disparity between gram-scale and kilogram-scale pricing is driven by economies of scale in the synthesis route. Laboratory synthesis often relies on manual handling and small reactor vessels, which limits throughput. Industrial production utilizes automated systems and continuous processing where applicable, drastically improving reaction yields and reducing labor costs.
Furthermore, industrial batches allow for more efficient solvent recovery systems. In the production of this Benzoic acid 4,5-bis(2-methoxyethoxy)-2-nitro- ethyl ester, solvents such as DMF or acetonitrile are used in significant quantities. At the kilogram scale, distillation and recycling units can recover up to 80% of these solvents, a saving that is passed down to the buyer in the form of lower bulk prices. Buyers focusing solely on unit price without considering purity specifications risk downstream purification costs that far exceed the initial savings.
Requesting Quotations for 2026 Supply Contracts
Securing supply for 2026 requires proactive engagement with manufacturers. Raw material costs for nitro-aromatics and etherifying agents are subject to global petrochemical trends. Locking in prices through forward contracts can mitigate budget volatility. Procurement teams should request quotations that specify validity periods, payment terms, and Incoterms.
When contacting NINGBO INNO PHARMCHEM CO.,LTD., ensure that the request for quotation (RFQ) includes detailed specifications regarding particle size, residual solvent limits, and heavy metal content. These parameters are critical for regulatory filings. A reliable supplier will provide a comprehensive COA (Certificate of Analysis) with every batch, ensuring traceability and compliance with international health authority guidelines.
In conclusion, the market for Ethyl 4,5-Bis(2-Methoxyethoxy)-2-Nitrobenzoate remains robust due to its essential role in kinase inhibitor manufacturing. By prioritizing industrial purity and establishing strong relationships with capable manufacturers, pharmaceutical companies can secure a stable supply chain for 2026 and beyond. Strategic bulk procurement not only optimizes costs but also ensures the quality consistency required for life-saving medications.